Avance Clinical and Medidata Celebrate Strategic Partnership and Inhouse Expert Accreditation Mil. The leading Australian CRO for biotechs, and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical continues to celebrate their strategic partnership with Medidata, and the accreditation of seven Medidata inhouse experts.
BriefingWire.com, 2/26/2021 - The two organizations have been working together to deliver world-class clinical research services to Avance Clinical s biotech customers via the Medidata Rave Clinical Cloudâ¢.
Avance Clinical, Chief Strategy Officer, Ben Edwards said We look forward to many more years working with Medidata as we continue to grow the business and support the development needs of our clients.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
OncoSec Medical Announces Proposed Public Offering of Common Stock
January 20, 2021 GMT
OncoSec Medical Incorporated logo (PRNewsfoto/OncoSec Medical Incorporated)
PENNINGTON, N.J. and SAN DIEGO, Jan. 20, 2021 /PRNewswire/ OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares to be sold in the offering will be offered by O
Share this article
Share this article
PENNINGTON, N.J. and SAN DIEGO, Jan. 19, 2021 /PRNewswire/ OncoSec Medical Incorporated (NASDAQ:ONCS) (the Company or OncoSec ) today announced it entered into an agreement with Sirtex Medical, Inc. (Sirtex) granting Sirtex an option to non-exclusively co-promote the Company s lead product candidate, TAVO™ (tavokinogene telseplasmid) in anti-PD-1 checkpoint refractory metastatic melanoma in the U.S. By entering into this co-promotion, OncoSec intends to capitalize on both the extensive experience Sirtex has in marketing drug/device combination products, as well as their established oncology sales force in the U.S.
Daniel O Connor, President and Chief Executive Officer of OncoSec, stated, Sirtex is a strong company with significant experience in the sales and marketing of drug/device combination products to treat cancer. This deal provides OnocSec with the potential to commercialize TAVO with a highly skilled U.S. sales force in this
Share this article
Share this article
SEOUL, Korea, Jan. 13, 2021 /PRNewswire/ StradVision, a leading innovator in AI-based camera perception software for Advanced Driver Assistance Systems (ADAS) and Autonomous Vehicles (AV), today announced its collaboration with D3 Engineering on an Automotive Front Camera solution delivering market-leading performance and price efficiency.
The solution integrates a D3 DesignCore® platform for product development with StradVision s deep learning based front camera software SVNet . In this collaboration, StradVision provides 6 key perception features of SVNet including Lane Detection, Traffic Sign Detection, Traffic Light Detection, Vehicle Detection, Pedestrian Detection, and Free Space Detection to this virtual demo platform.